DBV Technologies Revenue and Competitors
Estimated Revenue & Valuation
- DBV Technologies's estimated annual revenue is currently $1.6M per year.
- DBV Technologies's estimated revenue per employee is $6,996
- DBV Technologies's current valuation is $185.3M. (January 2022)
Employee Data
- DBV Technologies has 223 Employees.
- DBV Technologies grew their employee count by 1% last year.
DBV Technologies's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP | Reveal Email/Phone |
2 | CEO / Directeur General | Reveal Email/Phone |
3 | SVP, Head Global Quality | Reveal Email/Phone |
4 | VP Clinical Development and Medical Affairs | Reveal Email/Phone |
5 | SVP Engineering, Manufacturing et Supply | Reveal Email/Phone |
6 | Chief Legal Officer | Reveal Email/Phone |
7 | Senior Director, Medical & Scientific Communications and Information | Reveal Email/Phone |
8 | Product Director | Reveal Email/Phone |
9 | CHIEF SCIENTIFIC OFFICER | Reveal Email/Phone |
10 | Senior Director, Head, Global Communications, Public & Government Affairs | Reveal Email/Phone |
DBV Technologies Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is DBV Technologies?
DBV Technologies is a clinical-stage biopharmaceutical company developing treatments to help those with food allergies. With a new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of product candidates in Phase III, Phase II, and preclinical development. DBV is also pursuing a human proof-of-concept clinical study using their technology for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. Allergy, Food and pediatric allergy, Specific immunotherapy
keywords:N/A
N/A
Total Funding
223
Number of Employees
$1.6M
Revenue (est)
1%
Employee Growth %
$185.3M
Valuation
N/A
Accelerator
DBV Technologies News
JMP Securities dropped their target price on shares of DBV Technologies from $8.00 to $5.00 and set a market outperform rating for the company...
DBV Technologies. Statutory auditors' report on the financial statements December 31, 2021. For the year ended December 31, 2021.
DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company,...
DBV Technologies Reports Third Quarter 2021 Financial Results and Recent Regulatory Developments DBV Technologies S.A. (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter of 2021. T ...
DBV Technologies S.A. Proxy Statement for the 2021 Annual Combined General Meeting of Shareholders Dear Fellow Shareholders, DBV Technologies was founded on the belief that children with food allergies, their families, and the allergists who treat them, need and deserve multiple treatment op ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 223 | 18% | $44.7M |
#2 | $51.5M | 223 | 12% | N/A |
#3 | $66.2M | 223 | 10% | N/A |
#4 | $52.2M | 223 | -2% | N/A |
#5 | $58.3M | 223 | -12% | $28.4M |